Showing results (91-100 of 136) with videos related to

Sort By:
Pageof 14
British Journal of Haematology|October 12, 2013
Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myelomaJonathan L Kaufman, Ruben Niesvizky, Edward A Stadtmauer, et al.
Cancer|July 18, 2000
Carcinoembryonic antigen immunoscintigraphy complements mammography in the diagnosis of breast carcinomaD M Goldenberg, H Abdel-Nabi, C L Sullivan, et al.
Methods (San Diego, Calif.)|April 26, 2005
Development of humanized antibodies as cancer therapeuticsZhengxing Qu, Gary L Griffiths, William A Wegener, et al.
Rheumatology (Oxford, England)|November 26, 2013
Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006Vibeke Strand, Michelle Petri, Kenneth Kalunian, et al.
Leukemia & Lymphoma|September 22, 2015
Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemiaMatt E Kalaycio, O George Negrea, Steven L Allen, et al.
Frontiers in Psychology|May 9, 2015
Sugarcoated isolation: evidence that social avoidance is linked to higher basal glucose levels and higher consumption of glucoseTsachi Ein-Dor, James A Coan, Abira Reizer, et al.
Nature Communications|December 24, 2017
Protein conformational flexibility modulates kinetics and thermodynamics of drug bindingM Amaral, D B Kokh, J Bomke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2005
Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumabOla Lindén, Cecilia Hindorf, Eva Cavallin-Ståhl, et al.
Elife|July 20, 2014
Orbitofrontal neurons acquire responses to 'valueless' Pavlovian cues during unblockingMichael A McDannald, Guillem R Esber, Meredyth A Wegener, et al.
Haematologica|December 22, 2010
Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphomaGeorge O Negrea, Rebecca Elstrom, Steven L Allen, et al.
Pageof 14